Literature DB >> 21681410

Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.

Naoki Hiramatsu1, Masayuki Kurosaki, Naoya Sakamoto, Manabu Iwasaki, Minoru Sakamoto, Yoshiyuki Suzuki, Fuminaka Sugauchi, Akihiro Tamori, Sei Kakinnuma, Kentaro Matsuura, Namiki Izumi.   

Abstract

BACKGROUND: This study aimed to develop a model to predict the development of severe anemia during pegylated interferon alpha-2b plus ribavirin combination therapy.
METHODS: Data were collected from 1081 genotype 1b chronic hepatitis C patients who were treated at 6 hospitals in Japan. These patients were randomly assigned to a model-building group (n = 691) or an internal validation group (n = 390). Factors predictive of severe anemia (hemoglobin, Hb < 8.5 g/dl) were explored using data-mining analysis.
RESULTS: Hb values at baseline, creatinine clearance (Ccr), and an Hb concentration decline by 2 g/dl at week 2 were used to build a decision-tree model, in which the patients were divided into 5 subgroups based on variable rates of severe anemia ranging from 0.4 to 11.8%. The reproducibility of the model was confirmed by the internal validation group (r² = 0.96). The probability of severe anemia was high in patients whose Hb value was <14 g/dl before treatment (6.5%), especially (a) in those whose Ccr was <80 ml/min (11.8%) and (b) those whose Ccr was ≥ 80 ml/min but whose Hb concentration decline at week 2 was ≥ 2 g/dl (11.5%). The probability of severe anemia was low in the other patients (0.4-2.5%).
CONCLUSIONS: The decision-tree model that included Hb values at baseline, Ccr, and an Hb concentration decline by 2 g/dl at week 2 was useful for predicting the probability of severe anemia, and has the potential to support clinical decisions regarding early dose reduction of ribavirin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681410     DOI: 10.1007/s00535-011-0412-z

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

2.  Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.

Authors:  Masayuki Kurosaki; Naoya Sakamoto; Manabu Iwasaki; Minoru Sakamoto; Yoshiyuki Suzuki; Naoki Hiramatsu; Fuminaka Sugauchi; Hiroshi Yatsuhashi; Namiki Izumi
Journal:  J Gastroenterol       Date:  2010-09-10       Impact factor: 7.527

3.  Factors influencing ribavirin-induced hemolysis.

Authors:  H Van Vlierbergh; J R Delanghe; M De Vos; G Leroux-Roel
Journal:  J Hepatol       Date:  2001-06       Impact factor: 25.083

4.  Improved detection of prostate cancer using classification and regression tree analysis.

Authors:  Mark Garzotto; Tomasz M Beer; R Guy Hudson; Laura Peters; Yi-Ching Hsieh; Eduardo Barrera; Thomas Klein; Motomi Mori
Journal:  J Clin Oncol       Date:  2005-03-21       Impact factor: 44.544

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

Authors:  J F Jen; P Glue; S Gupta; D Zambas; G Hajian
Journal:  Ther Drug Monit       Date:  2000-10       Impact factor: 3.681

7.  ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

Authors:  Hidenori Ochi; Toshiro Maekawa; Hiromi Abe; Yasufumi Hayashida; Rikita Nakano; Michaki Kubo; Tatsuhiko Tsunoda; C Nelson Hayes; Hiromitsu Kumada; Yusuke Nakamura; Kazuaki Chayama
Journal:  Gastroenterology       Date:  2010-07-14       Impact factor: 22.682

8.  Phosphorus ans an early predictive factor in patients with acute liver failure.

Authors:  Angeles Baquerizo; Dean Anselmo; Christopher Shackleton; Teng-Wei Chen; Carlos Cao; Michael Weaver; Jeffrey Gornbein; Sunil Geevarghese; Nicholas Nissen; Douglas Farmer; Achilles Demetriou; Ronald W Busuttil
Journal:  Transplantation       Date:  2003-06-27       Impact factor: 4.939

9.  Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.

Authors:  N Hiramatsu; T Oze; T Yakushijin; Y Inoue; T Igura; K Mochizuki; K Imanaka; A Kaneko; M Oshita; H Hagiwara; E Mita; T Nagase; T Ito; Y Inui; T Hijioka; K Katayama; S Tamura; H Yoshihara; Y Imai; M Kato; Y Yoshida; T Tatsumi; K Ohkawa; S Kiso; T Kanto; A Kasahara; T Takehara; N Hayashi
Journal:  J Viral Hepat       Date:  2009-06-22       Impact factor: 3.728

10.  Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.

Authors:  Shintaro Takaki; Akihito Tsubota; Tetsuya Hosaka; Norio Akuta; Takashi Someya; Masahiro Kobayashi; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2004-07       Impact factor: 7.527

View more
  9 in total

1.  Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.

Authors:  Akihito Tsubota; Noritomo Shimada; Hiroshi Abe; Kai Yoshizawa; Rie Agata; Yoko Yumoto; Makiko Ika; Yoshihisa Namiki; Keisuke Nagatsuma; Hiroshi Matsudaira; Kiyotaka Fujise; Norio Tada; Yoshio Aizawa
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

2.  Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.

Authors:  Nader Nemr; Rania Kishk; Mohamed Mandour
Journal:  Indian J Gastroenterol       Date:  2016-02-16

3.  Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.

Authors:  Kazuyuki Imakiire; Hirofumi Uto; Yuko Sato; Fumisato Sasaki; Seiichi Mawatari; Akio Ido; Kazuya Shimoda; Katsuhiro Hayashi; Sherri O Stuver; Yoshito Ito; Takeshi Okanoue; Hirohito Tsubouchi
Journal:  Mol Med Rep       Date:  2012-05-21       Impact factor: 2.952

4.  Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels.

Authors:  Hirofumi Uto; Seiich Mawatari; Kotaro Kumagai; Akio Ido; Hirohito Tsubouchi
Journal:  Hepat Mon       Date:  2012-02-29       Impact factor: 0.660

Review 5.  Advanced molecular surveillance of hepatitis C virus.

Authors:  Livia Maria Gonçalves Rossi; Alejandro Escobar-Gutierrez; Paula Rahal
Journal:  Viruses       Date:  2015-03-13       Impact factor: 5.048

6.  Validation of the usefulness of artificial neural networks for risk prediction of adverse drug reactions used for individual patients in clinical practice.

Authors:  Shungo Imai; Yoh Takekuma; Hitoshi Kashiwagi; Takayuki Miyai; Masaki Kobayashi; Ken Iseki; Mitsuru Sugawara
Journal:  PLoS One       Date:  2020-07-29       Impact factor: 3.240

7.  A model predicting short-term mortality in patients with advanced liver cirrhosis and concomitant infection.

Authors:  Ying Li; Roongruedee Chaiteerakij; Jung Hyun Kwon; Jeong Won Jang; Hae Lim Lee; Stephen Cha; Xi Wei Ding; Charat Thongprayoon; Fu Shuang Ha; Cai Yun Nie; Qian Zhang; Zhen Yang; Nasra H Giama; Lewis R Roberts; Tao Han
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

8.  Phosphoinositide 3-kinase-delta could be a biomarker for eosinophilic nasal polyps.

Authors:  Jong Seung Kim; Jae Seok Jeong; Kyung Bae Lee; So Ri Kim; Yeong Hun Choe; Sam Hyun Kwon; Seong Ho Cho; Yong Chul Lee
Journal:  Sci Rep       Date:  2018-10-30       Impact factor: 4.379

9.  Combining genetic risk score with artificial neural network to predict the efficacy of folic acid therapy to hyperhomocysteinemia.

Authors:  Xiaorui Chen; Xiaowen Huang; Diao Jie; Caifang Zheng; Xiliang Wang; Bowen Zhang; Weihao Shao; Gaili Wang; Weidong Zhang
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.